Akebia signs up Quintiles for Phase III study
Akebia Therapeutics has signed a master services agreement with CRO Quintiles in connection with its planned Phase III studies for Akebia’s lead product candidate for the treatment of anemia secondary to chronic kidney disease in non-dialysis patients.
Under the terms of the three-year deal, Quintiles agreed to provide trial services including statistical analysis, data processing, data management, and project management, according to an SEC filing.
Akebia will retain exclusive rights to all inventions, discoveries, ideas, processes, products, trade secrets, know-how, data, and all other products and/or materials arising from or made in the performance of services under the agreement, while Quintiles has agreed to assign its rights in all such inventions and related patents to the Company.
